Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS
نویسندگان
چکیده
منابع مشابه
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
OBJECTIVE To determine the time to efficacy onset of glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40). METHODS This post hoc analysis of data from the 1-year, double-blind, placebo-controlled phase of the Glatiramer Acetate Low-Frequency Administration study (NCT01067521) of GA40 in patients with relapsing-remitting MS (RRMS) sought to determine the timing of efficacy onset ...
متن کاملAdherence to Glatiramer Acetate 40 Mg Versus Oral Disease-Modifying Therapies for Multiple Sclerosis.
GA 40 mg TIW cohort: patients with GA 40 mg on their index dates or who switched to GA 40 mg during post-index and had ≥90 days of post-index after switch; for switchers, the date of the switch to GA 40 mg became the new index date n=232 Oral DMT cohort: patients whose index DMTs were ngolimod, teri unomide, or dimethyl fumarate and who did not switch to GA 40 mg TIW during post-index n=1,547 F...
متن کاملAnaphylaxis to Glatiramer Acetate
Glatiramer acetate (Copaxone, Teva Pharma) and interferon beta are the two only disease-modifying therapies for multiple sclerosis. Glatiramer acetate is known for frequently simulating mild, anaphylactoid reactions while true, IgEmediated allergic reactions have been hardly reported so far. Herein, we report two females suffering from multiple sclerosis who experienced rapidly aggravating hype...
متن کاملTherapy with glatiramer acetate for multiple sclerosis.
BACKGROUND Some clinical data have shown that glatiramer acetate (Copaxone), a synthetic amino acid polymer empirically found to suppress experimental allergic encephalomyelitis (EAE), an animal model of MS, might help improve the outcome of patients with multiple sclerosis (MS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of glatiramer acetate in MS...
متن کاملReversible alopecia associated with glatiramer acetate.
W e describe a 42-year-old woman with relapsingremitting multiple sclerosis (MS) who developed alopecia while receiving pharmacotherapy with glatiramer acetate (GA). The patient was diagnosed with relapsing-remitting MS in 1998 based on her clinical presentation, positive surrogate disease markers on magnetic resonance imaging, and the presence of multiple oligoclonal bands in her cerebrospinal...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis and Related Disorders
سال: 2019
ISSN: 2211-0348
DOI: 10.1016/j.msard.2019.04.036